Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in juvenile psoriatic arthritis and enthesitis-related arthritis
NL-OMON45692Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis, enthesitis-related (JIA-ERA) comparing Secukinumab continuation with Placebo withdrawal (2 arms). Primary endpoint: Time to flare during Treatment Period 2. Planned start Jan 2017; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on NL-OMON45692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45692.